Compass Pathways (CMPS) announced that the U.S. FDA has accepted its Investigational New Drug application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways enters strategic collaboration with Radial Health
- Buy Rating for COMPASS Pathways: Anticipated Phase 3 Data to Shape COMP360’s Future in Treatment-Resistant Depression Market
- Psychedelic: Atai Beckley granted U.S. patent for EMP-01
- Compass Pathways upgraded to Outperform at Oppenheimer on COMP360 potential
- Compass Pathways upgraded to Outperform from Perform at Oppenheimer